- Home
- APLT vs ETW Comparison
APLT vs ETW Comparison
Compare APLT & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- ETW
- Stock Information
- Founded
- APLT 2016
- ETW 2005
- Country
- APLT United States
- ETW United States
- Employees
- APLT N/A
- ETW N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- ETW Investment Managers
- Sector
- APLT Health Care
- ETW Finance
- Exchange
- APLT Nasdaq
- ETW Nasdaq
- Market Cap
- APLT 44.0M
- ETW 939.4M
- IPO Year
- APLT 2019
- ETW N/A
- Fundamental
- Price
- APLT $0.41
- ETW $8.70
- Analyst Decision
- APLT Buy
- ETW
- Analyst Count
- APLT 7
- ETW 0
- Target Price
- APLT $6.10
- ETW N/A
- AVG Volume (30 Days)
- APLT 2.6M
- ETW 284.6K
- Earning Date
- APLT 08-06-2025
- ETW 01-01-0001
- Dividend Yield
- APLT N/A
- ETW 8.61%
- EPS Growth
- APLT N/A
- ETW N/A
- EPS
- APLT N/A
- ETW N/A
- Revenue
- APLT $265,000.00
- ETW N/A
- Revenue This Year
- APLT $1,768.13
- ETW N/A
- Revenue Next Year
- APLT $292.85
- ETW N/A
- P/E Ratio
- APLT N/A
- ETW N/A
- Revenue Growth
- APLT N/A
- ETW N/A
- 52 Week Low
- APLT $0.30
- ETW $6.96
- 52 Week High
- APLT $10.62
- ETW $8.49
- Technical
- Relative Strength Index (RSI)
- APLT 58.87
- ETW 65.02
- Support Level
- APLT $0.32
- ETW $8.60
- Resistance Level
- APLT $0.36
- ETW $8.73
- Average True Range (ATR)
- APLT 0.04
- ETW 0.06
- MACD
- APLT 0.01
- ETW 0.01
- Stochastic Oscillator
- APLT 94.92
- ETW 92.05
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.